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ABSTRACT:  
 
The natural product cyclic peptide stylissatin A (1a), was reported to inhibit nitric oxide 
production in LPS-stimulated murine macrophage RAW 264.7 cells. In the current study, solid-
phase total synthesis of stylissatin A was performed by using a safety-catch linker and yielded 
the peptide with a trans-Pro6-Phe7 linkage whereas the natural product is the trans rotamer at this 
position as evidenced by a marked difference in NMR chemical shifts. In order to preclude the 
possibility of 1b beingan epimer of the natural product, we repeated the synthesis using D-allo-
Ile in place of L-Ile and a different site formacrocyclization.The resulting product (D-allo-Ile2)-
stylissatin A (1c)was also found to have the trans-Pro6-Phe7 peptide conformations like rotamer 
1b. Applying the second routeto the synthesis of stylissatin A itself, we obtained stylissatin A 
natural rotamer 1a accompanied by rotamer 1b as the major product. Rotamers 1a, 1b and the 
epimer 1c were separable by HPLC and 1a was found to match the natural product in structure 
and biological activity. Six related analogues 2-7 of stylissatin A were synthesized on Wang 
resin and characterized by spectral analysis. The natural product (1a), the rotamer (1b), and (D-
allo-Ile2)-stylissatin A (1c) exhibited significant inhibition of NO.. Further investigations were 
focused on 1b, which also inhibited proliferation of T-cells and inflammatory cytokine IL-2 
production. The analogues 2-7 weakly inhibited NO. production, but strongly inhibited IL-2 
cytokine production compared to synthetic peptide 1b. All analogues inhibited the proliferation 
of T-cells, with analogue 7 having the strongest effect. In the analogues, the Pro6 residue was 
replaced by Glu/Ala and the SAR indicates that the nature of this residue plays a role in the 
biological function of these peptides.   
 
 
 
 
 
Keywords: solid-phase peptide synthesis, cyclic peptides, proline rotamers, inflammation, nitric 
oxide, interleukin 2, reactive oxygen species. 
 
INTRODUCTION: 
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Recently, the cyclic peptide stylissatin A (1) has been isolated from the Papua New Guinean 
marine sponge Stylissa massa. The cyclic peptide 1 was reported to have an inhibitory effect on 
nitric oxide production in LPS-stimulated murine macrophage RAW264.7 cells with an IC50 
value of 87 µM [1]. Inflammation is an immediate cellular response of the body against harmful 
foreign elements and tissue injury. Upon first exposure to pathogens or other stimuli phagocytes, 
mainly neutrophils and macrophages, release various mediators including reactive oxygen (ROS) 
and nitrogen species (RNS), chemokines and cytokines. The release of these mediators 
progresses the processes of inflammation and activation of cell mediated immune responses 
[2,3]. Reactive oxygen species (ROS) and nitric oxide (NO.) released by inflammatory cells are 
involved directly and indirectly in the advancement of oxidative damage [4]. Nitric oxide (NO.) 
has various physiological roles including maintenance of vessel homeostasis. However, the 
excessive production of NO. in inflammatory conditions has a damaging effect on cells and 
organs [5,6]. Meanwhile, T lymphocytes are the main cells involved in the generation of 
adaptive immune response. The activation and proliferation of various immune cells depends on 
the cytokines secreted by T- cells. IL-2 is an important immunomodulatory cytokine, secreted by 
T-cells. Along with the effect on production of other cytokines, it is known to activate T-cells in 
an autocrine manner. Activated T-cells have high affinity receptors for IL-2 on their surface [7]. 
Inhibition of IL-2 provides a strong immunosuppressive response by preventing the activation 
and proliferation of T-cells in transplantation rejection and other autoimmune diseases [8]. 
Given the interesting structure of stylissatin A (1a) with the inclusion of two proline residues that 
can exist as cis or trans rotamers and the biological activity in reducing NO. release, we 
embarked on investigations to complete the total synthesis of stylissatin A and a set of analogues 
to explore structure-activity relationships. During the course of our study, the synthesis of 
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stylissatin A was reported by a combination of solid and solution-phase synthesis and the 
synthetic sample also exhibited strong inhibition against NO. release (EC50 73 µM) [9]. Although 
the proline rotatmers of the synthetic and natural stylissatin A were not assigned, analysis of the 
reported 13CNMR data indicates that both are the trans, cis proline rotamers with a trans-peptide 
bond between Pro4-Ile5 and a cis-peptide bond between Pro6-Phe7.  
RESULTS AND DISCUSSION: 
Among various synthetic methods to cyclic peptides, the on-resin cyclization approach has been 
successfully employed in the synthesis of several biologically active natural peptides.  Several 
procedures have been developed for on-resin cyclization in good yields with minimum side 
products [10-12]. For the synthesis of peptide 1, we selected Kenner's sulfonamide safety-catch 
linker strategy as employed previously for cyclic peptides by others [13-16] as well as ourselves 
[17-19]. In our first synthesis (route A), Fmoc-L-isoleucine was employed for loading on the 
sulphamylbutyryl Kenner safety-catch resin. Using Fmoc solid-phase peptide synthesis, the 
head-to-tail coupling of amino acids was carried out to produce the linear peptide precursor of 1. 
The Fmoc group of the terminal amino acid Tyr was replaced by Boc before activation of the 
safety-catch linker through alkylation with iodoacetonitrile. The Boc group was then removed by 
using a TFA cocktail. Base treatment promoted on-resin macrocyclization between Ile and Tyr 
residues of the linear precursor to produce the cyclic peptide 1b which was simultaneously 
cleaved from the resin (Scheme 1).  
Reverse-phase recycling HPLC with an isocratic solvent system was used in the purification of 
the major product 1b. A comparison of NMR chemical shifts of natural stylissatin 1a and 
synthetic peptide 1b in d6-DMSO were performed (Table 1). Whereas, natural stylissatin A (1a) 
is the trans, cis rotamer at the Pro4-Ile5 and Pro6-Phe7 peptide bonds respectively as inferred from 
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analysis of 13CNMR chemical shift differences of Cβ−Cγ of Pro4 and Pro6  residues of natural 
product, he synthetic peptide 1b from this study was found to be the trans, trans rotamer [19-22] 
as revealed by 13CNMR chemical shift differences of Pro Δδ Cβ−Cγ i.e., (Pro4, Δδ Cβ (29.0)−Cγ 
(24.5) = 4.5 and Pro6, Δδ Cβ (29.1) − Cγ (24.6) = 4.5) (Figure 1).  In the NOESY spectrum clear 
cross-peaks were observed between Ile5-H/Pro4-HA and Pro4-HB as well as between Phe7-
H/Pro6-HA, and Pro6-HB (Figure S8), that further supported the trans conformation of all 
proline peptidic linkages of 1b which is in accordance with the literature [20,23,24]. This change 
in proline rotamer to trans-Pro6-Pro7 led to global changes in the NMR chemical shifts in 
synthetic 1b compared to the natural 1a as reported for other proline peptide conformers [22]. 
Our results combined with the previous synthesis [9] indicate the proline rotamer population can 
be significantly influenced by the macrocyclization method used. 
In route A, since the isoleucine residue was activated and involved in the macrocyclization step, 
another possible explanation is that the differences in chemical shifts between 1a and 1b may be 
due to epimerization at Ile2 during macrocyclization [9]. In order to preclude the possibility of 1b 
as an epimer of the natural product, we carried out a second synthesis (route B) in which the 
macrocyclization was taking place at a different position between tyrosine and phenylalanine 
residues (Scheme 2). Furthermore, in this synthesis, we deliberately replaced L-Ile2 by D-allo-
Ile2 to ensure full epimerization at this position. Afterh this synthesis, the peptide 1c was purified 
and analyzed by reverse-phase high performance liquid chromatography. It showed a different 
retention time (Figure 2) and distinct 1HNMR data compared to 1b (Table 1). Detailed NMR 
studies revealed that 1c also has trans-Pro4-Ile5 and trans-Pro6-Phe7 peptide conformations 
(13CNMR chemical shift differences of Pro Δδ Cβ−Cγ i.e., (Pro4, Δδ Cβ (28.9) − Cγ (24.3) = 4.6 
and Pro6, Δδ Cβ (28.6) − Cγ (24.4)= 4.1) (Figure 1).  The prominent cross peaks between Ile5-
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H/ Pro4-HA and Pro4-HB as well as between Phe7-H/ Pro6-HA, and Pro6-HB confirmed 
the trans linkage of both Pro4 and Pro6 residues (Figure S9).Although both 1b and 1c contain 
trans proline rotamers, they were distinct species and this confirms that 1b is in fact a proline 
rotamer of natural stylissatin A (1a) rather than an epimer at the Ile2 residue (Table-1).  
The synthesis of stylissatin A was then performed using route B (Scheme 3) with L-Ile2 to 
investigate whether the site of cyclization affects the rotamer populationDespite the different 
position of macrocyclization, the synthesis one again afforded the trans, trans proline rotamer 1b 
as the major product as determined by HPLC and NMR comparison with the sample from route 
ANevertheless, a small amount of a second product was obtained that we were able to isolate and 
spectroscopically characterize as identical to the trans, cis natural product rotamer 1a(Table-1). 
Synthetic stylissatin A 1a had 13CNMR chemical shift differences of Pro Δδ Cβ−Cγ i.e., (Pro4, Δδ 
Cβ (29.3) − Cγ (24.6) = 4.7 and Pro6, Δδ Cβ (29.5) − Cγ (21.6)= 7.9) (Figure 1) that matched the 
literature reports although asample of naturally isolated stylissatin A was not available for direct 
comparison. The cross-peak between Pro6-Η/ Phe7-Η in ROESY spectrum established the cis-
geometry for the Pro6-Phe7 peptide bond [22] (Figure S10). Stylissatin A (1a), its proline amide 
rotamer (1b) and its epimer (1c) have different retention time under similar HPLC conditions and 
can be distinguished from one another (Figure 2).  
 
Many proline-rich synthetic cyclic peptides such as stylopeptides, axinastins and 
cherimolacyclopeptide E have not reproduced the biological activity reported forthe naturally 
isolated material[19, 24]. One reason for this discrepancy is cis / trans isomerization at proline 
linkages in such peptides having an effect on the bioactivity [24]. In the current study, despite the 
rotamer difference, our synthetic sample of stylissatin A 1a and its rotamer 1b show similar 
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nitric oxide inhibitory activity. This reveals that the  cis / trans conformation of the Pro6 residue 
in stylissatin A has no impact on biological activity of these peptides. 
In order to better understand the structure-activity relationships of stylissatin A, we 
embarked on the synthesis of six analogues 2-7 (Table-2) (Scheme 4). Given the potential for 
multiple rotamers with the safety-catch strategy, we switched to an on-resin cyclization approach 
using the Wang resin [25-28]. Linear precursors of peptide analogues were anchored to the 
Wang resin through the side chain of glutamic acid. Fmoc-peptide coupling and Fmoc group 
deprotection followed standard procedures that were used in the natural product synthesis. After 
the synthesis of the linear chain, the allyl protecting group of the Glu residue was removed by 
using palladium (0) (Scheme 1). The Fmoc group of the terminal amino acid residue was 
removed by 4-methylpiperidine in DMF. On-resin cyclization (27-29) was carried out by using 
Oxymapure / DIC and a TFA cocktail cleaved the final product from the resin. The structures of 
analogues were confirmed by MALDI (Table S1) and NMR studies (Table 3,4). Purification of 
all peptides was achieved by using preparative HPLC. 
The peptide 1b and related six analogues 2-7 were evaluated for their anti-inflammatory 
potential by investigating different immune parameters including effects on production of NO
.
, 
intracellular ROS and interleukin 2 (IL-2) cytokine (Table 5). The natural product (1a), the synthetic 
proline amide rotamer of stylissatin A (1b), and (D-allo-Ile2)-stylissatin A (1c) exhibited significant 
inhibition of NO. produced from LPS activated J774.2 macrophages with an IC50 value in the 
range of 60-69 μM, while the standard nitric oxide inhibitor L-NMMA had an IC50 = 97.5 μM. 
Further investigations were focused on peptide 1b and its related analogues 2-7. No inhibition 
was observed when 1b was tested for its effect on ROS produced from whole blood and isolated 
neutrophils from the blood of healthy human volunteers. The peptide showed strong inhibitory 
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effect against proliferation of T-cells whereas it moderately inhibited the production of cytokine 
interleukin 2 (IL-2) (Table-5). 
The analogues 2-7 showed weak inhibitory activity of NO. and more potent inhibition of 
interleukin 2 production compared to parent peptide 1. The common difference among the 
peptide sequence of natural peptide 1 and 2-7 is that Pro6 is replaced by other amino acid 
residues in all analogues.  That resulted in varying biological activity of natural peptide and its 
analogues (Table 5). It also appeared that by substitution of both proline residues (Pro4 and Pro6) 
of peptide 1, with Ala and Glu respectively, the resulting peptide analogue 2 was found to be a 
strong inhibitor of ROS with no inhibition of NO..  It potently inhibited ROS from neutrophils as 
well as strongly inhibited the release of cytokine interleukin 2 (IC50 13.4 ± 0.1 μM) (Table 5). 
This indicated that both proline residues are involved in the mechanism of NO. inhibition. The 
peptide analogue 7, in which Ile2 and Pro6 were replaced by Ala and Glu, respectively, was 
found to be the most potent inhibitor of interleukin 2 (IC50 6.0 ± 0.9 μM) release among the 
peptides 1-7. The results obtained from current studies showed significant anti-inflammatory 
potential of synthetic peptide 1b and its analogues 2-7. 
 
CONCLUSION 
Stylissatin A (1a), proline rotamer of stylissatin A (1b), an epimer (1c) and six cyclic analogues 
2-7 were successfully synthesized on solid-phase by employing different cyclization routes. All 
peptides were characterized by mass and NMR studies. The position of macrocyclization was 
found to influence the proline rotamer population of synthetic sytlissatin A. Synthetic stylissatin 
1a was found to have similar activity to that reported in the literature. The synthetic stylissatin A 
1a and its trans, trans rotamer 1b potently inhibited the NO. production. Analogue 2 inhibited 
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ROS on whole blood, as well as neutrophils. Related analogues of stylissatin A were identified 
as more potent inhibitors of interleukin 2 release.  
 
EXPERIMENTAL SECTION 
General Experimental Procedures. Bruker 600 MHz NMR spectrometer were used for Proton 
and Carbon-13 NMR spectra. NMR data were collected at 25°C. ESI mass spectra were recorded 
on QSTAR XL MS/MS SYSTEMS (AB SCIEX, USA). Matrix-assisted laser 
desorption/ionization was carried out on Ultraflex III TOF/TOF (Bruker Daltonics, Bremen, 
Germany) mass spectrometer. Preparative RPHPLC separation was performed by using a Jaigel 
ODS-MAT 80 (C18) column using elution with acetonitrile / water (60:40) in 0.08 % TFA. 
Optical rotation was measured with a JASCO DIP 360 polarimeter at the sodium D line (path 
length 50 mm). 
Stylissatin A Synthesis. 4-Sulfamylbutyryl-aminomethyl resin (0.7 mmol/g) from Novabiochem 
and was used in the synthesis. Solid-phase synthesis was accomplished manually by using a step-
wise Fmoc solid-phase peptide procedure. Agitations were performed with an orbital shaker or 
magnetic stirrer. Synthesis of linear peptidyl chain was achieved by applying same procedure as 
reported previously [16, 18, 19]. 
  Cleavage of Peptides from Resin after Cyclization. After activation of linker and removal of 
Boc group from terminal amino acid  as shown in scheme 1-3, the peptide resin was soaked in 
THF. It was then treated with 20 % DIEA / THF for 24 h in nitrogen atmosphere. The resin was 
filtered and washed with THF and DCM (3 × 25 mL each) and the filtrate was collected. After 
evaporation of solvents under reduced pressure, the crude cyclized product was precipitated with 
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cold diethyl ether, and dried in vacuum. The crude peptides were precipitated from cold diethyl 
ether and further purified on RPHPLC. 
Synthesis of Stylissatin A Analogues: Solid phase peptide synthesis of all analogues was 
accomplished by using a step-wise Fmoc solid-phase peptide procedure; all reagents were from 
Chem-Impex USA and Novabiochem. Wang resin (loading capacity; 0.9 mmol/g) was used as 
solid support. Fmoc-Glu(OAllyl)–OH was coupled to resin first in all six analogues by using 
oxymapure and diisopropylcarbodiimide (DIC) in dichloromethane (DCM) / dimethylformamide 
(DMF). After loading the first amino acid (AA), the resin was treated with acetic anhydride (2 
equiv.) and Pyridine (2 equiv.) in DCM for 30 min to cap un-reacted hydroxyl groups. Linear 
peptide resins were synthesized using Fmoc AAs with oxymapure / DIC as coupling reagents 
and 20 % 4-methyl piperidine in DMF for Fmoc group deprotection. After completing the linear 
peptide sequences, the allyl group of the glutamic acid was removed using Pd-catalyst (tetrakis 
(triphenylphosphine) palladium (0) (0.51 equiv.) in an inert environment in mixture of DCM / 
acetic acid / NMM of 18.5:1:0.5. After washing, the Fmoc of terminal AA was deprotected by 
treatment with 20 % 4-methylpiperidene in DMF. The macrocyclization was performed as 
previously reported [29]. A cocktail of trifluoroacetic acid / DCM / triisopropylsilane of 
19:0.8:0.2 v/v was used to cleave the peptide from resin. Filtrates containing crude peptide were 
concentrated and precipitated using cold diethyl ether and further purified on RPHPLC. 
Chemiluminescence assay: The luminol-enhanced chemiluminescence assay was performed, as 
described by Jantan et al [30]. 
Nitric oxide Assay: The nitric oxide assay was performed on mouse macrophage cell line J774.2 
(European Collection of Cell Cultures, UK) using three different concentrations (2, 10 and 50 
μM) of peptide and with method as described in Shaheen et al [31]. 
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IL-2 Production and Quantification: 
Jurkat (human T lymphocyte leukemia) cells were maintained in RPMI-1640 (BioM 
Laboratories, Chemical Division, Malaysia) supplemented with 5% FBS and 1% penicillin / 
streptomycin (GIBCO New York U.S). Upon 70% confluency cells were plated in 96-well flat 
bottom plates (Costar, NY, USA) at a concentration of 2×106 cells/mL. The cells were activated 
by using 20 ng/mL of phorbol myristate acetate (PMA) and, 7.5 µg/mL of phytoheamagglutinin 
(PHA) (SERVA, Heidelberg, Germany). Cells were then treated with three different 
concentrations (2, 10, 50 μM) of compound and plate was incubated for 18 hours at 37 ºC in 5% 
CO2. Supernatants were collected and IL-2 quantification was performed using the human IL-2 
Kits Duo Set (R&D systems, Minneapolis, USA) and according to manufacturer’s instructions 
[32].  
T-cell Proliferation Assay. 
Cell proliferation assay performed by standard thymidine, incorporation assay [20]. Briefly, T-
cells were isolated from peripheral blood of healthy volunteers using Ficoll paque method. The 
cells were plated at a concentration of 2 ×106 cells/mL in a round bottom 96-well tissue culture 
plates IWAKI (Chiba, Japan). Peptides were added in three different concentrations (2, 10 and 
50 μM) in triplicates. The plates were then incubated for 48hrs at 37 °C in 5% CO2 incubator. 
After 48 hrs, cultures were pulsed with 0.5 µCi / well (methyl-3H) thymidine Amersham 
Pharmacia (Biotech, UK), and further incubated for 18 hrs. Thymidine incorporation into the 
cells was measured by a LS65000 liquid scintillation counter Beckman coulter (Fullerton, CA, 
USA). Results were expressed as mean count per minute (CPM). 
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Table 1: NMR data of stylissatin A (1a) rotamer (1b) and epimer (1c) in DMSO-d6 
 
Residue Positions Synthetic 
Rotamer  (1b)  
Epimer 
(1c)  
Stylissatin A 
Reported data 
Natural Product 
1a from Route b 
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[1] 
  Ca Hb Ca Hb H Ca Hb 
Tyr1 NH  7.69(1H, 
d, 8.9) 
 8.32 (d, 
8.3) 
7.20 (1H, d, 
4.7) 
 7.20 
  56.6  
 
4.10(1H, 
m)  
54.9 4.23, m 4.07(1H, ddd, 
9.8, 4.7, 2.6) 
55.5 4.05 (1H, 
m) 
  37.5 2.59 (1H, 
dd, 9.0, 
13.8) 
35.9 2.34 (m) 3.09(1H, dd, 
13.1, 2.6) 
36.4 3.07 
 
 
   2.69 (1H, 
dd, 5.0, 
13.8) 
 2.89 (m) 2.67(1H, dd)  2.65 
(1H,dd, 
13.3, 3.0) 
 1 128.9  129.9   128.2  
 2,6 130.1 6.98 (2H, 
d, 8.4) 
129.0 6.93 
(8.3) 
7.19 (2H, d) 129.6 7.12 
(2H, 7.8) 
 3,5 115.8 6.66 (2H, 
d, 8.4) 
114.7 6.55 
(8.4) 
6.70 (2H, d) 114.7 6.68 (2H, 
8.0) 
 4 155.8  155.6   156.0  
 CO 169.4  170.8   170.0  
 OH  9.3 (1H, 
bs) 
 9.01 8.54 (1H, s)   
Ile2 NH  7.90(1H, 
bs) 
 8.15 (d, 
6.4) 
7.34(1H, d)  7.33 
  53.2 3.89 (1H, 
m) 
57.9 3.80 (t, 
7.3) 
4.19(1H, dd) 59.5 4.19 
  36.3 1.72 (1H, 
m) 
34.9 1.32 1.46 (1H, m) 36.8 1.43 
  24.3 1.52 (1H, 
m) 
24.1 0.90 (m) 
 
1.45 (1H, m) 24.1 1.47 
   1.34 (1H, 
m) 
 0.65 (m) 1.10 (1H, m)  1.10 
 ’ 15.1 0.81 (3H, 
d, 6.6) 
14.6 0.27 (d, 
6.6) 
0.85 (3H, d, 
6.7) 
14.4 0.83 t 
(6.6) 
  11.2 0.78 (3H, 
m) 
10.4 0.55 (t, 
7.0) 
0.78 (3H, t, 7.1) 9.9 0.78 
(7.3) 
 CO 170.2  171.2   171.5  
Phe3 NH  8.00 
(1H,m) 
 7.82 (d, 
7.4) 
8.45(1H, d, 6.7)  8.44 d 
(6.6) 
  54.0 4.47(1H, 
dd, 4.8, 
8.0) 
53.6 4.63 (t, 
7.5. 
14.6) 
3.71(1H, ddd, 
11.4, 6.7, 6.6) 
57.7 3.69 
ddd(4.2, 
6.5, 11.3) 
  36.9 2.99(1H, 
m) 
38.7 2.80 
5.7, 
13.5 
3.42 (1H) 34.0 3.42 
(1H, m) 
 
   2.82(1H,   2.92 
m 
3.25 (1H)  3.22 
(1H, m) 
 1 137.9  137.6   139.1  
 2,6 128.0 7.22 (m)c 128.2 7.24 
(2H)c 
7.19 (2H, brd) 129.6 7.19(2H)c 
 3,5 126.1 7.18 (m)c 126.0 7.12 
(2H) c 
7.27 (2H, br, t) 128.2 7.25(2H)c 
 4 129.2 7.24 (bs)\c 129.9 7.16 
(1H)c 
7.31 (1H, br) 129.1 7.28(1H)c 
 CO 170.9  171.0   171.1  
Pro4  59.2 4.43(1H, 59.3 4.43 3.88 (1H, m) 60.5 3.86 (t) 
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dd, 7.8, 
13.8)  
(1H, m)  (7.6) 
  29.1 1.97 (1H, 
m) 
28.9 1.97 
(1H, m) 
1.78 (1H, m) 29.3 
 
1.73 
   1.76 (1H, 
m) 
 1.82 
(1H, m) 
1.67(1H, m)  1.67 
  24.4 1.74 (1H, 
m) 
24.3 1.83 
(1H, m) 
2.00 (1H, m) 24.6 1.97 
   1.82 (1H, 
m) 
 1.81 
(1H, m) 
1.73(1H, m)  1.65 
  46.9 3.50 (1H, 
m) 
47.1 3.48 
(1H, m) 
4.26(1H, m) 48.6 4.27 (1H, 
m) 
   3.64 (1H, 
m) 
 3.65 
(1H, m) 
3.57(1H, m)  3.52 (1H, 
m) 
 CO 169.4  169.8   169.8  
Ile5 NH  7.98 (1H, 
m) 
 7.91 
(1H)  
9.41 (1H, d)  9.4 d 
(8.4) 
  54.5 4.34 (1H, 
m) 
54.1 4.42 
(1H, m) 
4.22(1H, dd) 54.8 4.22 
  36.7 1.76 (1H, 
m) 
36.5 1.82 
(1H, m) 
2.02(1H, m) 34.8 1.98 
  24.0 1.05 (1H, 
m) 
23.7 1.06 
(1H, m) 
1.45(1H, m) 23.9 1.42 
 
   1.52 (1H, 
m) 
 1.50 
(1H, m) 
1.10(1H, m)  1.05 
 ’ 15.4  0.86 (3H, 
d, 6.6) 
10.9 0.89 
(3H, d, 
6.2) 
0.86 (3H, d, 
6.7) 
14.7 0.89 (d, 
6.3) 
  10.9    0.80 (3H, 
m) 
15.3 0.75 
(3H, t, 
7.5) 
0.79 (3H, t, 7.1) 9.5 0.75 (t, 
7.2) 
 CO 171.2  170.8     
Pro6  59.1 4.32 (1H, 
m) 
59.6 4.28 
(1H, m) 
3.99(1H, m) 60.4 3.32(1H,
m) 
  29.0 1.98 (1H, 
m) 
28.6 1.83 2.28(1H, m) 29.5 1.90 
   1.74 (1H, 
m) 
 1.98 1.50(1H, m)  0.65 
  24.5 1.79 (1H, 
m) 
24.5 1.82 1.95(1H, m) 21.6 1.95 
   1.83 (1H, 
m) 
 1.79 1.59(1H, m)  1.65 
  47.1 3.49 (1H, 
m) 
46.9 3.45 3.30 (2H, m) 45.7 3.19 
   3.54 (1H, 
m) 
 3.63   3.24 
 CO 171.2  170.8   169.1  
Phe7 NH  8.14(1H, 
7.74) 
 7.92 (m) 8.77 (1H, br s)   
  52.3 4.68 (1H, 
m)  
 
51.6 
 
4.78 
(8.5, 
13.3) 
4.01 (1H, brdd) 53.8 3.99 (4.3, 
11.4) 
  36.6 2.80(1H, 
m) 
38.1 3.06 
(3.9, 
13.9)   
2.89 (1H, dd) 37.1 2.88 (4.2, 
12.1) 
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   3.01(1H, 
m) 
 2.95 
(1H, m) 
2.63 (1H, dd)  2.62 (m) 
 1 137.3  137.6   135.2  
 2,6 128.3 7. 15 
(2H)c  
128.2 7.25 
(2H)c 
7.13 (2H, br d) 131.0 7.18 
 3,5 126.5 7. 23  
(2H)c 
126.5 7.20(2H)
c 
7.27 (2H, br t) 126.9 7.17 
 4 129.2 7.25 (1H)c 129.3 7.28 
(1H)c 
7.31 (1H, br t) 128.6 7.29 
 CO 169.9  169.9   169.2  
 
aRecorded at 150 MHz. Multiplicity was derived from the DEPT and HSQC spectra.  
bRecorded at 600 MHz. Coupling constants (Hz) are shown in parentheses. 
cSignals overlapped. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Characterization data of peptides 1-7 
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Peptide substituted 
 residue 
[M+H]+  Sequence of compound [α]D25 Overall 
Yield 
% 
      
1a none 
 
878.4631 (C49H64N7O8) 
 
cyclo (Pro6-Phe7-Tyr1-Ile2-Phe3-Pro4-Ile5) 
 
-29.76 (c 0.0672, 
MeOH) 
2.3(route 
A 
 1b none 
 
 
900.4630 (C49H64N7 NaO8) cyclo (Pro6-Phe7-Tyr1-Ile2-Phe3-Pro4-Ile5) 
 
 
−40 (c 0.11, MeOH) 
 
4.1(route 
B 
 
1c none 
 
900.4644 (C49H64N7 NaO8) 
 
cyclo (Pro6-Phe7-Tyr1-ile2-Phe3-Pro4-Ile5) -24.7 (c 0.0932, 
MeOH) 
5.9(route 
C) 
2 
 
Pro6, Pro4 
 
883.4474 (C47H61N7O10) 
906.4372 (C47H61N7O10Na) 
 
cyclo (Glu6-Phe7-Tyr1-Ile2-Phe3-Ala4-Ile5) −21.8 (c 0.055 MeOH) 18.7  
 
3 
 
Pro6, Pro4 
 
883.4474 (C47H61N7O10) 
906.4372 (C47H61N7O10Na) 
 
cyclo (Ala6-Phe7-Tyr1-Ile2-Phe3-Glu4-Ile5) 
 
−47.6 (c 0.05 MeOH) 
 
16.1 
 
4 Pro6, Phe7 
 
833.4318 (C43H59N7O10) 
856.4216 (C43H59N7O10Na) 
cyclo (Glu6-Ala7-Tyr1-Ile2-Phe3-Pro4-Ile5) −77.3(c 0.052 MeOH) 
 
16.5 
 
5 Pro6, Phe3 
 
833.4318 (C43H59N7O10) 
856.4216 (C43H59N7O10Na) 
 
cyclo (Glu6-Phe7-Tyr1-Ile2-Ala3-Pro4-Ile5) −49.5(c 0.047 MeOH) 
 
13.1 
 
6 Pro6, Tyr1 
 
817.4368 (C43H59N7O9) 
840.4266 (C43H59N7O9Na) 
 
cyclo (Glu6-Phe7-Ala1-Ile2-Phe3-Pro4-Ile5) 
 
−71.1(c 0.06 MeOH) 
 
15.1 
 
7 Pro6, Ile2 867.4161 (C46H57N7O10) 
890.4059 (C46H57N7O10Na) 
cyclo (Glu6-Phe7-Tyr1-Ala2-Phe3-Pro4-Ile5) −60.3(c 0.055 MeOH) 19.5 
 
 
 
 
 
 
 
Table 3: H1 and C13 NMR data of Peptides 2-4 in DMSO d6 
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2 3 4 
Residue C13 H1 Residue C13 H1 Residue C13 H1 
         
Tyr1  7.85 Tyr1   Tyr1   
NH   NH  7.89 NH  8.16 
α 54.4 4.42 α 53.8 4.44 α 53.8 4.42 
β 37.4 2.65 β 37.0 2.59 β 35.5 2.78 
  2.82   2.79   2.94 
1 136.0  1 137.5  1 137.6  
2,6 129.9 6.95 2,6 130.0 6.94 2,6 129.1 6.99 
3,5 114.8 6.57 3,5 114.7 6.56 3,5 114.8 6.62 
4 155.7  4 155.9  4 155.7  
CO 170.75  CO 170.1  CO 170.6  
OH  9.1 OH  9.1 OH  9.18 
Ile2   Ile2   Ile2   
NH  7.71 NH  7.91 NH  7.88 
α 56.5 4.12 α 56.78 4.14 α 56.6 4.10 
β 36.1 1.60 β 36.8 1.58 β 36.3 1.62 
γ 23.9 1.03 γ 24.0 0.95 γ 24.0 1.23 
  1.35   1.28   0.95 
γ’ 11.0 0.65 γ’ 14.60 0.66 γ’ 10.82 0.70 
δ 15.2 0.76 δ 14.88 0.78 δ 15.00 0.74 
CO 170.45  CO 170.46  CO 172.84  
Phe3   Phe3    Phe3   
NH  8.06 NH  7.78 NH  8.01 
α 53.5 4.51 α 56.0 4.18 α 53.9 4.33 
β 36.5 2.74 β 36.54 2.99 β 28.5 2.81 
  2.93   2.78   2.62 
1 137.6  1 137.5  1 137.69  
2,6 129.1 7.16 2,6 128.2 7.21 2,6 129.98 7.19 
3,5 127.9 7.15 3,5 127.8 7.22 3,5 127.98 7.18 
4 126.8 7.15 4 127.5 7.23 4 126.12 7.19 
CO 173.8  CO 170.92  CO 167.69  
Ala4   Glu4   Pro4   
NH  7.90 NH  7.85 α 51.3 4.26 
α 47.9 4.25  52.5 4.4 β 29.2  1.96 
β 18.2 1.13 β  29.8 2.6   1.86 
CO 172.6    2.8 γ 23.7 1.03 
Ile5   γ 27.7 1.98   1.46 
NH  7.1   1.84 δ 46.6 3.69 
α 58.9 3.84 CO 173    3.44 
β 36.6 1.65 COOH 174  CO 170.61  
γ 24.3 1.26 Ile5   Ile5   
  1.30 NH  7.9 NH  7.72 
γ’ 11.0 0.75 Α 56.78 4.16 α 54.3 4.26 
δ 15.3 0.74 Β 36.9 1.61 β 36.0 1.65 
CO 170.45  Γ 24.2 1.27 γ 23.8 1.79 
Glu6     1.32   1.93 
NH  7.1 γ’ 15.3 0.67 γ’ 10.96 0.75 
α 58.9 3.80 δ 12.2 0.75 δ 15.15 0.71 
β  30.1 2.21 CO 170.51  CO 169.08  
  2.32 Ala6   Glu6   
γ 28.5 1.90 NH  8.15 NH  8.16 
  1.70 α 48.08 4.34 α 59.20 4.32 
CO 166.2  β 18.1 1.18 β  29.0 2.37 
COOH 173.8  CO 172.5    2.38 
Phe7   Phe7   γ 27.7 2.35 
NH  7.99 NH  8.07   2.25 
α 53.1 4.49 α 53.4 4.52 CO 167.69  
β 36.9 2.82 β 37.07 2.79 COOH 173.94  
  3.15   2.99 Ala7   
1 135.97  1 138.4  NH  8.14 
2,6 130.33 7.13 2,6 129.00 7.22 α 47.2 3.85 
3,5 130.29 6.95 3,5 129.18 7.23 β 18.9 1.25 
4 130.00 7.12 4 128.29 7.21 CO 172.0  
CO 166.27  CO 170.12     
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Table 4:  H1 and C13 NMR data of Peptides 5-7 in DMSO d6. 
5 6  7 
Residue C13 H1 Residue C13 H1 Residue C13 H1 
         
Tyr1   Ala1   Tyr1   
NH  8.18 NH  7.99 NH  8.02 
α 55.2 4.18 α 48.1 4.29 α 53.6 4.34 
β 37.9 2.82 β 18.1 1.12 Β 36.94 2.62 
  3.10 CO 172.8    2.85 
1 135.9  Ile2   1 135.9  
2,6 129.1 6.92 NH  8.18 2,6 130.0 6.92 
3,5 114.7 6.56 α 56.6 4.12 3,5 114.7 6.58 
4 155.7  β 36.1 1.65 4 155.7  
CO 167.0  γ 24.1 1.35 CO 170.4  
OH  9.10   1.47 OH  9.11 
Ile2   γ’ 14.9 0.81 Ala2   
NH  7.6 δ 10.8 0.72 NH  7.9 
α 56.2 4.08 CO 170.6  α 48.6 4.17 
β 36.5 1.59 Phe3   β 18.2 1.09 
γ 24.0 1.79 NH  7.897 CO 172.8  
  1.82 α 53.5 4.48 Phe3   
γ’ 10.8 0.70 β 37.2 2.77 NH  7.88 
δ 15.1 0.62   2.83 α 54.0 4.38 
CO 170.5  1 137.5  β 37.3 2.78 
Ala3   2,6 130.3 7.12   2.95 
NH  8.01 3,5 129.1 7.19 1 135.9  
α 48.1 4.18 4 126.1 7.14 2,6 130.2 7.10 
β 17.5 1.13 CO 171.8  3,5 129.2 7.25 
CO 172.5  Pro4   4 128.0 7.28 
Pro4   α 59.2 4.34 CO 169.9  
α 59.1 4.32 β 28.5 1.77 Pro4   
β 28.6 1.70   1.79 α 59.2 4.32 
  1.20 γ 24.2 1.76 β 29.0 1.73 
1.70 
γ 24.3 1.22   1.13    
  1.05 δ 47.12 3.51 γ 24.1 1.48 
1.49 
δ 47.1 3.52   3.69    
  3.72 CO 170.34  δ 47.1 3.49 
CO 166.3  Ile5     3.68 
Ile5   NH  8.18 CO 170.8  
NH  8.07 α 51.3 4.30 Ile5   
α 54.9 4.31 β 36.1 1.68 NH  8.07 
β 36.1 1.70 γ 24.1 1.71 α 54.6 4.28 
γ 24.2 1.50   1.79 β 37.9 1.70 
  1.78 γ’ 15.1 0.7 γ 24.3 1.02 
γ’ 11.0 0.81 δ 10.9 0.84   1.2 
δ 14.9 0.88 CO 170.3  γ’ 14.9 0.82 
CO 170.0  Glu4   δ 10.8 0.78 
Glu6   NH  8.21 CO 170.6  
NH  7.82 α 51.5 4.30 Glu6   
α 51.1 4.32 β  29.7 2.15 NH  8.07 
β  30.2 2.22   2.25 α 51.5 4.29 
  2.26 γ 28.6 1.79 β  29.8 2.26 
2.28 
γ 28.5 1.79   1.80    
  1.98 CO 170.7  γ 28.2 1.70 
CO 172.0  COOH 173.8    1.85 
COOH 173.7  Phe7   CO 170.7  
Phe7   NH  7.89 COOH 174.0  
NH  8.2 α 53.8 4.48 Phe7   
α 52.9 4.51 β 37.2 2.78 NH  7.8 
β 37.9 2.81   2.96 α 53.9 4.34 
  3.15 1 137.5  β 36.0 2.83 
1 135.9  2,6 127.9 7.14   2.92 
2,6 130.4 7.12 3,5 129.2 7.19 1 135.9  
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3,5 128.3 7.23 4 126.1 7.18 2,6 130.0 7.14 
4 126.7 7.17 CO 171.3  3,5 128.5 7.07 
CO 166.2     4 127.9 7.15 
      CO 170.8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Effect of peptides on oxidative burst, Nitric oxide (NO) and IL-2 production and 
T-cell proliferation. 
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L-NMMA= NG Monomethyl L-arginine acetate 
Nd (not determined) 
 
 
 
 
 
Compound 
No. 
Oxidative Burst (IC50μM) NO. 
(IC50μM) 
IL-2 
(IC50 μM) 
T-cell 
Proliferation 
(IC50 μM) 
Whole Blood Neutrophils  
1a 
1b 
1c 
nd 
>100 
nd 
 
nd 
>100 
nd 
 
   63.0 ± 5.4 
60 ± 4.5 
   69.7 ± 2.3 
nd 
43.5 ± 5.6 
nd 
nd 
8.76 ± 2.1 
nd 
 
2 40.3 ± 7.1 15.0 ± 1.2 >200 13.4 ± 0.1 14.5 ± 2.1 
3 >100 >100 154.6 ± 9 23.4 ± 0.2 40.6 ± 1.6 
4 >100 >100 135.5 ± 19.2 18.2 ± 1.4 12.37 ± 2.1 
5 >100 >100 128.6 ± 6 17.0 ± 2.0 56.7 ± 0.6 
6 >100 >100 141.7 ± 20 14.9 ± 1.5 27.9 ± 0.4 
7 >100 >100 137.8 ± 17.3 6.0 ± 0.9 10.9 ± 3.0 
Ibuprofen 54.3 ± 9.2 12.1 ± 2.9 - -  
L-NMMA - - 97.5 ± 3.2 -  
Cyclosporin - - - <0.06 1.5 ± 0.2 
 
